Recombinant triple human papillomavirus (16/18/58) vaccine (kangle biotechnology)

重组三价人乳头瘤病毒（16/18/58型）疫苗（康乐卫士生物）

Report date: 2025/04/23 10:02:58

Base Information

Drug NameRecombinant triple human papillomavirus (16/18/58) vaccine (kangle biotechnology)
Drug Alias NameN/A
ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical DysplasiaNeoplasm InvasivenessVulvar Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesAihui Import And Export Process For Russia Heihe City HeilongjiangBeijing Health Guard Biotechnology IncTaizhou Tiande Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesKangle Guardian (Kunming) Biotechnology Co LtdTaizhou Tiande Pharmaceutical Co LtdAihui Import And Export Process For Russia Heihe City Heilongjiang +[4] 
Inactive CompaniesN/A
Active IndicationsUterine Cervical DysplasiaNeoplasm InvasivenessVulvar Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A